Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# BridgeBio Oncology Therapeutics

BBOT: Best-in-RAS

## Sitemaps

- [XML Sitemap](https://bbotx.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models](https://bbotx.com/wp-content/uploads/BBO-11818-AACR-2026.pdf#new_tab)
- [The RAS:PI3Kα Breaker BBO-10203 inhibits PI3Kα/AKT activity in HER2<sup>AMP</sup> models through non-canonical RAS signaling blockade](https://bbotx.com/wp-content/uploads/BBO-10203-AACR-2026.pdf#new_tab)
- [Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants](http://bbotx.com/wp-content/uploads/BBO-11818-Cancer-Discovery-Publication.pdf#new_tab)
- [BREAKER-101: A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Patients with Advanced Solid Tumors](https://bbotx.com/wp-content/uploads/BREAKER-101-SABCS-2025-poster-layout-19-Nov-2025-UPLOAD.pdf#new_tab)
- [BBO-10203, a first-in-class breaker of the RAS:PI3Kα interaction, inhibits tumor growth alone and in combination with fulvestrant or ribociclib in breast cancer models without inducing hyperglycemia](https://bbotx.com/wp-content/uploads/BBO-10203-SABCS-2025-poster_final.pdf#new_tab)
- [BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia](http://bbotx.com//wp-content/uploads/BBO-10203-AACR-NCI-EORTC-triple-poster-2025.pdf#new_tab)
- [BBO-11818: an orally bioavailable, highly potent and selective noncovalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models](http://bbotx.com/wp-content/uploads/BBO-11818-Triple-2025-Poster-new-dimensions-final.pdf#new_tab)
- [BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer](https://bbotx.com/news/bbot-appoints-industry-veteran-uneek-mehra-as-chief-financial-officer/)
- [BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction](http://bbotx.com/wp-content/uploads/Science_BBO-10203-inhibits-tumor-growth-without-inducing-hyperglycemia-by-blocking-RAS-PI3Ka-interaction.pdf#new_tab)
- [BBOT Announces Publication in Science Highlighting Preclinical Data that Supports the Potential for RAS:PI3Kα Breaker BBO-10203 to Provide Therapeutic Benefit across Multiple Tumor Types](https://bbotx.com/news/bbot-announces-publication-in-science-highlighting-preclinical-data-that-supports-the-potential-for-raspi3kα-breaker-bbo-10203-to-provide-therapeutic-benefit-across-multiple-tumor-types/)
- [BBO-8520, a first-in-class direct dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRAS<sup>G12C</sup>, exhibits robust efficacy in non-small cell lung cancer preclinical models](http://bbotx.com/wp-content/uploads/Stice_AACR_BBO-8520_Final.pdf#new_tab)
- [BBO-11818, an orally bioavailable, highly potent and non-covalent pan-KRAS inhibitor demonstrates robust anti-tumor activity in KRAS-mutant preclinical models](http://bbotx.com/wp-content/uploads/BBO-11818-AACR-Poster-final.pdf#new_tab)
- [BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors](https://bbotx.com/news/bridgebio-oncology-therapeutics-bbot-announces-first-patient-dosed-with-first-in-class-bbo-10203-a-raspi3kα-breaker-in-the-phase-1-breaker-101-trial-for-advanced-solid-tumors/)
- [BBO-8520, a First-in-Class, Direct Inhibitor of KRAS<sup>G12C</sup> (ON)](https://bbotx.com/wp-content/uploads/Hanson-Wade-2023-Final.pdf#new_tab)
- [BBO-8520 Preclinical Data Published in Cancer Discovery Supports the Potential for the First-in-Class Molecule to Provide Therapeutic Benefit in KRAS<sup>G12C</sup> Mutant Tumors](https://bbotx.com/news/bbo-8520-preclinical-data-published-in-cancer-discovery-supports-the-potential-for-the-first-in-class-molecule-to-provide-therapeutic-benefit-in-krasg12c-mutant-tumors/) - TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT” or the “Company”), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the publication of preclinical data supporting the hypothesis that targeting both “ON” and “OFF” forms of KRASG12C results in greater potency, deeper responses, and slowed development of resistance leading to significant benefits over “OFF” only KRASG12C inhibitors approved in non-small cell lung cancer (NSCLC).
- [BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRAS<sup>G12C</sup>-Mutated Metastatic Non-Small Cell Lung Cancer](https://bbotx.com/news/bridgebio-oncology-therapeutics-bbot-granted-u-s-fda-fast-track-designation-for-bbo-8520-for-krasg12c-mutated-metastatic-non-small-cell-lung-cancer/) - TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT” or the “Company”), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BBO-8520, an investigational oral therapy for the treatment of adult patients with previously treated, KRASG12C-mutated metastatic non-small cell lung cancer (NSCLC).
- [BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors](https://bbotx.com/news/bbot-announces-first-patient-dosed-with-bbo-11818-a-pankras-dual-inhibitor-in-the-phase-1-konquer-101-trial-for-advanced-solid-tumors/)
- [BBO-11818, an orally bioavailable, highly potent and non covalent pan-KRAS inhibitor demonstrates robust anti-tumor activity in KRAS<sup>G12D</sup> and KRAS<sup>G12V</sup> preclinical models](http://bbotx.com/wp-content/uploads/BBO-11818-RAS-Symposium-Poster_10012024_NG-1.pdf#new_tab)
- [BBO-8520, a First-in-Class, Direct Inhibitor of KRAS<sup>G12C</sup> (ON), Locks GTP-Bound KRAS<sup>G12C</sup> in the State 1 Conformation Resulting in Rapid and Complete Blockade of Effector Binding](https://bbotx.com/wp-content/uploads/NDH-AACR-Final.pdf#new_tab)
- [BBO-8520, a first-in-class, direct, and covalent small molecule inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRAS<sup>G12C</sup>, demonstrates robust efficacy and compares favorably to GDP-bound KRAS<sup>G12C</sup> (OFF) only inhibitors in preclinical models](http://bbotx.com/wp-content/uploads/BBO-8520-RAS-symposium-Poster_vF-1.pdf#new_tab)
- [BBO-10203, a first-in-class breaker of the PI3Kα:RAS interaction, demonstrates in vitro and in vivo efficacy alone or in combination with standard-of-care therapies in solid tumor models](http://bbotx.com/wp-content/uploads/BBO-10203-Ras-Symposium-2024_v7_vfinal.pdf#new_tab)
- [BBO-10203, an orally bioavailable small molecule that disrupts the RAS:PI3Kα interaction leading to pAKT and tumor growth inhibition in models of breast, lung and colorectal cancer](http://bbotx.com/wp-content/uploads/ENA2024-Breaker-BBOT-vF_10.29.pdf#new_tab)
- [Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRAS<sup>G12C</sup>](http://bbotx.com/wp-content/uploads/Maciag-et-al-2024.pdf#new_tab)
- [BBO-10203, a first-in-class, orally bioavailable, selective blocker of the PI3Kα:RAS interaction inhibits tumor growth alone and in combination with standard of care therapies in breast cancer models without inducing hyperglycemia](http://bbotx.com/wp-content/uploads/PS7-04_Sinkevicius-PDF.pdf#new_tab)
- [Beyond First-Generation KRAS Inhibitors: BBO-8520 Tests the Dual Mechanism Hypothesis](http://bbotx.com/wp-content/uploads/Zhou-et-al_-1.pdf)
- [BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines](https://bbotx.com/news/bridgebio-oncology-therapeutics-bbot-and-helix-acquisition-corp-ii-announce-business-combination-agreement-to-create-publicly-listed-biotechnology-company-advancing-a-pipeline-of-ras-and-pi3kα/) - TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT”), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies, and Helix Acquisition Corp. II (Nasdaq: HLXB) (“Helix”), a special purpose acquisition company (SPAC) sponsored by affiliates of Cormorant Asset Management, today announced that they have entered into a definitive business combination agreement.
- [BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025](https://bbotx.com/news/bridgebio-oncology-therapeutics-bbot-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference-2025/) - TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT” or the “Company”), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that the company’s Chief Executive Officer, Eli Wallace, PhD, will provide a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:30 a.m. PT, and will host one-on-one investor meetings in San Francisco, CA.
- [BridgeBio Oncology Therapeutics announces first patient dosed with BBO-8520 in the Ph. 1 ONKORAS-101 trial for KRAS<sup>G12C</sup> NSCLC](https://bbotx.com/news/bridgebio-oncology-therapeutics-announces-first-patient-dosed-with-bbo-8520-in-the-ph-1-onkoras-101-trial-for-krasg12c-nsclc/)
- [BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer](https://bbotx.com/news/bridgebio-oncology-therapeutics-bbot-announces-the-appointment-of-yong-ben-md-as-chief-medical-and-development-officer/)
- [BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline](https://bbotx.com/news/bridgebio-launches-bridgebio-oncology-therapeutics-bbot-with-200m-of-private-external-capital-to-accelerate-the-development-of-its-novel-precision-oncology-pipeline/)
- [BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director](https://bbotx.com/news/bridgebio-oncology-therapeutics-bbot-appoints-praveen-tipirneni-md-to-its-board-of-directors-as-non-executive-director/)
- [Revealing the Mechanism of Action of a First-in-Class Covalent Inhibitor of KRAS<sup>G12C</sup> (ON) and Other Functional Properties of Oncogenic KRAS by <sup>31</sup>P NMR](https://bbotx.com/wp-content/uploads/Alok-PIIS0021925824000267.pdf#new_tab)
- [Targeting RAS-Driven PI3Kα Activation in Human Tumors](https://bbotx.com/wp-content/uploads/BB010203-SABCS23-Branded-Final.pdf#new_tab)
- [Targeting RAS-Driven PI3Kα Activation in Human Tumors](https://bbotx.com/wp-content/uploads/Salamanca-Breaker-presentation_vFinal.pdf#new_tab)
- [Use of the Natural Nucleotide, GTP, is Essential for the Identification of Potent, Active-State KRAS<sup>G12C</sup> Inhibitors That Bind in the Switch II Pocket](https://bbotx.com/wp-content/uploads/EORTCPoster23_GTPvsGppNHp-1.pdf#new_tab)

## Pages

- [Home](https://bbotx.com/) - Redefining what’s possible in precision oncology to treat RAS-dependent cancers. Inhibiting Active RAS. Going beyond current approaches.
- [Careers](https://bbotx.com/careers/) - Open positions
- [Open Positions](https://bbotx.com/open-positions/) - Open positions
- [About](https://bbotx.com/about/) - Taking Precision Oncology to New Heights. We are a clinical-stage company unraveling the complex role of RAS in cancer to drive drug discovery & development.
- [Contact Us](https://bbotx.com/contact-us/) - Taking Precision Oncology to New Heights. Get in touch with us. Are you interested in joining our team, learning more or partnering with us?
- [Pipeline](https://bbotx.com/pipeline/) - Rationally Designed to Maximize Patient Benefit. Overcoming limitations of current RAS-targeted approaches, aiming to realize full promise KRAS PI3K inhibition
- [Privacy Policy](https://bbotx.com/privacy-policy/) - BridgeBio Oncology Therapeutics shares your concerns about maintaining the integrity and privacy of personal information collected on the internet.
- [Terms of Use](https://bbotx.com/terms-of-use/) - PLEASE READ THESE TERMS OF USE CAREFULLY BEFORE USING THIS WEBSITE
- [News](https://bbotx.com/news/) - BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M private external capital to accelerate development of its novel precision oncology pipeline
- [Publications](https://bbotx.com/publications/)

## Team

- [Yong (Ben) Ben, MD, MBA](https://bbotx.com/team/yong-ben-ben-md-mba/)
- [Peter F. Lebowitz, MD, PhD](https://bbotx.com/team/peter-f-lebowitz/)
- [Frank McCormick, PhD](https://bbotx.com/team/frank-mccormick-ph-d/)
- [Jake Bauer, MBA](https://bbotx.com/team/jake-bauer-mba/)
- [Neil Kumar, PhD](https://bbotx.com/team/neil-kumar-ph-d/)
- [Idan Elmelech, MA, MBA](https://bbotx.com/team/idan-elmelech/)
- [Raymond Kelleher, MD, PhD](https://bbotx.com/team/raymond-kelleher-m-d-ph-d/)
- [Pedro J. Beltran, PhD](https://bbotx.com/team/pedro-beltran-ph-d/)
- [Marc Cobo](https://bbotx.com/team/marc-cobo/)
- [Sunyoung Lee, PhD, MS](https://bbotx.com/team/sunyoung-lee/)
- [Bihua Chen](https://bbotx.com/team/bihua-chen/)
- [Frank McCormick, PhD](https://bbotx.com/team/frank-mccormick/)
- [Zev Wainberg, MD](https://bbotx.com/team/zev-wainberg-md/)
- [Sara Hurvitz, MD, FACP](https://bbotx.com/team/sara-hurvitz-md-facp/)
- [Ben Solomon, MBBS, PhD, FRACP](https://bbotx.com/team/ben-solomon/)
- [Joon Whan Rhee, PhD](https://bbotx.com/team/joon-whan-rhee-phd/)
- [Hua Gong, MD, PhD](https://bbotx.com/team/hua-gong/)
- [Aaron Chan, JD](https://bbotx.com/team/aaron-chan/)
- [Praveen Tipirneni, MD](https://bbotx.com/team/praveen-tipirneni-md/)
- [Foster Gonsalves, PhD, MPH](https://bbotx.com/team/foster-gonsalves-ph-d/)
- [Chunmei Ji, PhD](https://bbotx.com/team/chunmei-ji-ph-d/)
- [Kerstin Sinkevicius, PhD](https://bbotx.com/team/kerstin-sinkevicius-ph-d/)
- [Rui Xu, PhD](https://bbotx.com/team/rui-xu-ph-d/)
- [Daniel Watson, PhD](https://bbotx.com/team/daniel-watson-ph-d/)
- [Bin Wang, PhD](https://bbotx.com/team/bin-wang-ph-d/)

## Categories

- [News](https://bbotx.com/category/news/)
- [2024](https://bbotx.com/category/news/2024-news/)
- [Publications](https://bbotx.com/category/publications/)
- [2023](https://bbotx.com/category/publications/year/2023/)
- [2024](https://bbotx.com/category/publications/year/2024/)
- [2025](https://bbotx.com/category/news/2025-news/)
- [2025](https://bbotx.com/category/publications/year/2025/)
- [Year](https://bbotx.com/category/publications/year/)
- [BBO-8520](https://bbotx.com/category/publications/type/bbo-8520/)
- [BBO-10203](https://bbotx.com/category/publications/type/bbo-10203/)
- [Type](https://bbotx.com/category/publications/type/)
- [BBO-11818](https://bbotx.com/category/publications/type/bbo-11818/)
- [2026](https://bbotx.com/category/publications/year/2026/)

## Portfolio Categories

- [BOD](https://bbotx.com/team/bod/)
- [Leadership](https://bbotx.com/team/leadership/)
- [CAB](https://bbotx.com/team/cab/)